Search

Displaying results 6921 - 6930 of 8170 in total
  1. Drug

    Gridegalutamide

    go.drugbank.com/drugs/DB21593
    Investigational

    Gridegalutamide has a monoisotopic molecular weight of 818.32 Da.

  2. Drug

    Docirbrutinib

    go.drugbank.com/drugs/DB21606
    Investigational

    Docirbrutinib has a monoisotopic molecular weight of 578.24 Da.

  3. Drug

    Tamuzimod

    go.drugbank.com/drugs/DB21621
    Investigational

    Tamuzimod has a monoisotopic molecular weight of 545.0 Da.

  4. Drug

    Lomedeucitinib

    go.drugbank.com/drugs/DB21649
    Investigational

    Lomedeucitinib has a monoisotopic molecular weight of 419.15 Da.

  5. Drug

    Bimokalner

    go.drugbank.com/drugs/DB21717
    Investigational

    Bimokalner has a monoisotopic molecular weight of 355.1 Da.

  6. Drug

    PRLX 93936

    go.drugbank.com/drugs/DB06098
    Investigational

    PRLX 93936 is selectively toxic to cancer cells.

  7. Drug

    Pam2csk4

    go.drugbank.com/drugs/DB16474
    Investigational

  8. Drug

    Dabocemagene autoficel

    go.drugbank.com/drugs/DB17878
    Investigational

    Dabocemagene autoficel is an _ex vivo_, autologous cell-based gene therapy. It comprises autologous dermal fibroblasts genetically modified to express functional type VII collagen.

    Synonyms: D-Fi, TRANSDUCED HUMAN AUTOLOGOUS DYSTROPHIC EPIDERMOLYSIS BULLOSA DERMAL FIBROBLAST CELL FCX-007 INTEGRATED PROVIRAL HUMAN COLLAGEN TYPE VII TRANSGENE COL7A1 PLUS 5'-HUMAN CYTOMEGALOVIRUS PROMOTER/UTR-AND 3'-LTR/PO
  9. Drug

    Viralym-C

    go.drugbank.com/drugs/DB17975
    Investigational

    Viralym-C is an investigational T-cell immunotherapy developed by ViraCyte. It consists of Human Leukocyte Antigen (HLA)-matched cytomegalovirus (CMV)-specific T lymphocytes.

  10. Drug

    BO-653

    go.drugbank.com/drugs/DB19216
    Investigational

    BO-653 is under investigation in clinical trial NCT00055510 (A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and